Literature DB >> 30945460

Legislation targeting head shops selling new psychoactive substances and changes in drug-related psychiatric admissions: A national database study.

Bobby P Smyth1,2,3, Antoinette Daly4, Khalifa Elmusharaf2, Conor McDonald5, Mary Clarke6, Sarah Craig4, Walter Cullen6.   

Abstract

AIM: New psychoactive substance (NPS) use can negatively impact mental health and may result in drug-related psychiatric admissions (DRPA). Irish youth reported very high rates of NPS use by international standards, the most common being synthetic cannabinoids and cathinones. This occurred in the context of a rapid expansion in specialist high street shops, called head shops, selling NPS in 2010. Government responded to public protests about head shops by enacting legislation in May and August 2010 to end this trade. Many academics argued that such actions were futile. We sought to determine if changes in head shop activity coincided with changes in DRPA.
METHOD: The national database on psychiatric admissions was examined focusing on young adults admitted from 2008 to 2012. Joinpoint regression analysis was utilized to examine for the presence of trend changes in DRPA.
RESULTS: The monthly rate of DRPA was higher in 2010 than 2008, 2009 and 2012 (P < 0.01). Joinpoint regression analysis identified a significant downward trend change which occurred in July 2010 (95% CI Feb 2010 to April 2011). Young males aged 18 to 24 years showed evidence of greatest change, DRPA falling by 1.4% per month (95% CI 0.7 to 3.7% decline) from May 2010 to December 2012.
CONCLUSIONS: Cessation of NPS sale by head shops coincided with a reversal in the upward trend of DRPA, this change being most evident in young men. While correlation does not imply causation, legislation which successfully targets the sale of NPS may result in reduced drug-related mental disorders.
© 2019 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  drug legislation; patient admission; psychiatry; public health; substance-related disorders

Mesh:

Substances:

Year:  2019        PMID: 30945460     DOI: 10.1111/eip.12807

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  2 in total

Review 1.  Understanding the UK Psychoactive Substances Act.

Authors:  Raymond G Hill
Journal:  Br J Clin Pharmacol       Date:  2020-01-03       Impact factor: 4.335

2.  Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.

Authors:  Adrian A Deen; Hugh Claridge; Richard D Treble; Hilary J Hamnett; Caroline S Copeland
Journal:  J Psychopharmacol       Date:  2021-06-29       Impact factor: 4.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.